INBIFO institut far biologische Forschung GmbH - Kéln PRIORITY

 

Addendum to Report P 0500/3237 97/10/9 Page 36

50 —-

40-4

30 +

SPECIFIC MUTAGENICITY (rev./mg TPM)

20

| Lao UU

cate of assay [5Mar.19Apr.0Sep] [5Mar.19Apr 0 Sep]

 

 

 

 

 

 

 

8028/970926

activation without $9 1 I with S9 l

Figure A8 Comparison of Specific Mutagenicity of TPM of VIRGO-CA in Strain TA1537

Remarks: mean + SD, N = 4 batches
results dated 10 Sep.97 from INBIFO study P 0500/3273

SQLLELLv90e